RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:75497

X-linked Ehlers-Danlos syndrome

high confidenceDisorder

Also known as: X-linked EDS · EDS V · Ehlers-Danlos syndrome type 5

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

78

38.6th percentile

Trials

0

Interventional, condition-specific

Researchers

234

Distinct authors in sample

Gene link

—

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare systemic disease characterized by a severe in all male patients, combining abnormality of connective tissue typical for Ehlers-Danlos syndrome (including joint hypermobility, scoliosis, soft and doughy skin, hyperextensible skin, abnormal scarring, facial peculiarities, and generalized , among others) and eventually lethal congestive heart failure due to polyvalvular disease. Female carriers are affected to a variable degree.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (1)

Ehlers-Danlos syndrome, X-linked

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    78 matched papers (22 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPartial

    None under the specific name; 43 for broader category Ehlers-Danlos syndrome

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

78

78 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

78 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

22 in the last 10 years · high confidence · 38.6th percentile (publications denominator)

Phrase hits: 78 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

234

Distinct author names in 78 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Pope FM5 papers · 2020

    Strangeways Research Laboratory, Addenbrooke's NHS Trust, Cambridge, UK.

    Papers in Europe PMC
  2. 02
    Beighton P4 papers · 1985
    Papers in Europe PMC
  3. 03
    Andersen PA2 papers · 2012
    Papers in Europe PMC
  4. 04
    Barry F2 papers · 2025

    Center for Research in Reproductive Health in Guinea (CERREGUI), Conakry, Guinea.

    Papers in Europe PMC
  5. 05
    Buller DB2 papers · 2012

    Klein Buendel, Inc., Golden, CO 80401, USA. dbuller@kleinbuendel.com

    Papers in Europe PMC
  6. 06
    Cutter GR2 papers · 2012
    Papers in Europe PMC
  7. 07
    Dignan MB2 papers · 2012
    Papers in Europe PMC
  8. 08
    Kane IL2 papers · 2012
    Papers in Europe PMC
  9. 09
    Letra A2 papers · 2018

    Center for Craniofacial Research, University of Texas Health Science Center School of Dentistry, Houston, 77054, USA. Ariadne.M.Letra@uth.tmc.edu.

    Papers in Europe PMC
  10. 10
    Maheshwari K2 papers · 2018

    Center for Craniofacial Research, University of Texas Health Science Center School of Dentistry, Houston, 77054, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 43 trials are registered for Ehlers-Danlos syndrome, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

high confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

43 interventional trials matched Ehlers-Danlos syndrome, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: Ehlers-Danlos syndrome

43

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"X-linked Ehlers-Danlos syndrome" OR "X-linked EDS" OR "EDS V" OR "Ehlers-Danlos syndrome type 5" OR "Ehlers-Danlos syndrome, X-linked"

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Ehlers-Danlos syndrome type 5

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"X-linked Ehlers-Danlos syndrome" OR "X-linked EDS" OR "EDS V" OR "Ehlers-Danlos syndrome type 5" OR "Ehlers-Danlos syndrome, X-linked"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"Ehlers-Danlos syndrome"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T01:49:44.578Z